GlassScriptPhysician profile
Issam Atallah
NPI 1487147971
$6,306.62
in general payments reported to CMS, 2019-2025
20 companies · $1,128 in 2025
The $1,128 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $12.40 · 2021: $363 · 2022: $881 · 2023: $2,476 · 2024: $1,321 · 2025: $1,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,711 · Travel and Lodging: $1,050 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,710.51 |
| Travel and Lodging | $1,050.33 |
| Education | $164.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $3,477.38 | 2022-2025 | Impella |
| Abbott Laboratories | $1,245.29 | 2021-2025 | Dragonfly Opstar, Amplatzer, Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $467.07 | 2021-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $235.86 | 2023-2024 | Camzyos |
| Shockwave Medical, INC | $166.95 | 2025 | |
| Medtronic, INC. | $164.28 | 2023 | Onyx Frontier |
| Teleflex LLC | $116.28 | 2022 | |
| Esperion Therapeutics, INC. | $76.04 | 2021 | |
| Merck Sharp & Dohme LLC | $71.04 | 2023-2024 | Verquvo, Belsomra |
| Janssen Pharmaceuticals, INC | $66.55 | 2019-2020 | |
| Cvrx, INC. | $41.95 | 2023 | Barostim Neo System |
| Edwards Lifesciences Corporation | $26.72 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $26.46 | 2019 | |
| Pfizer INC. | $25.37 | 2019 | |
| Getinge USA Sales, LLC | $23.71 | 2023 | Cardiosave Hybrid, Type B Plug |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $20.05 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $18.94 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.56 | 2024 | Jardiance |
| Boston Scientific Corporation | $14.53 | 2025 | Accolade Sr |
| Cardiovascular Systems INC. | $3.59 | 2023 | Diamondback Coronary |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Issam Atallah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.